Cited by 807Epigenetics and DNA MethylationCancer-related gene regulationChromatin Remodeling and Cancer

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells

Knutson, Sarah K, Wigle, Tim J, Warholic, Natalie M, Sneeringer, Christopher J, Allain, Christina J, Klaus, Christine R, Sacks, Joelle D, Raimondi, Alejandra, Majer, Christina R, Song, Jeffrey, Scott, Margaret Porter, Jin, Lei, Smith, Jesse J, Olhava, Edward J, Chesworth, Richard, Moyer, Mikel P, Richon, Victoria M, Copeland, Robert A, Keilhack, Heike, Pollock, Roy M, Kuntz, Kevin W·2012·Nature Chemical Biology

DOI 10.1038/nchembio.1084

Open this paper in CoChat — free account

Abstract

EZH2 catalyzes trimethylation of histone H3 lysine 27 (H3K27). Point mutations of EZH2 at Tyr641 and Ala677 occur in subpopulations of non-Hodgkin's lymphoma, where they drive H3K27 hypertrimethylation. Here we report the discovery of EPZ005687, a potent inhibitor of EZH2 (K(i) of 24 nM). EPZ005687 has greater than 500-fold selectivity against 15 other protein methyltransferases and has 50-fold selectivity against the closely related enzyme EZH1. The compound reduces H3K27 methylation in various lymphoma cells; this translates into apoptotic cell killing in heterozygous Tyr641 or Ala677 mutant cells, with minimal effects on the proliferation of wild-type cells. These data suggest that genetic alteration of EZH2 (for example, mutations at Tyr641 or Ala677) results in a critical dependency on enzymatic activity for proliferation (that is, the equivalent of oncogene addiction), thus portending the clinical use of EZH2 inhibitors for cancers in which EZH2 is genetically altered.

Integrity signals

Registry

Crossref · 10.1038/nchembio.1084

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors
Ben‐Porath, I., Thomson, M., Carey, V. J., Ge, R., Bell, G. W., Regev, A., & Weinberg, R. A. (2008) · Nature Genetics · doi:10.1038/ng.127 · Cited by 2,571
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
Morin, R. D., Johnson, N. A., Severson, T., Mungall, A. J. J., An, J., Goya, R., Paul, J. E., Boyle, M., Woolcock, B. W., Kuchenbauer, F. C., et al. (2010) · Nature Genetics · doi:10.1038/ng.518 · Cited by 1,719
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells
Kleer, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A., Ghosh, D., Sewalt, R. G. A. B., Otte, A. P., Hayes, D. F., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1933744100 · Cited by 1,649
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Morin, R. D., Mendez-Lago, M., Mungall, A. J., Goya, R., Mungall, K. L., Corbett, R. D., Johnson, N. A., Severson, T. M., Chiu, R., Field, M., et al. (2011) · Nature · doi:10.1038/nature10351 · Cited by 1,614
Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein
Kuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P., & Reinberg, D. (2002) · Genes & Development · doi:10.1101/gad.1035902 · Cited by 1,596
UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development
Agger, K., Cloos, P. A., Christensen, J. F., Pasini, D., Rose, S., Rappsilber, J., Issaeva, I., Canaani, E., Salcini, A. E., & Helin, K. (2007) · Nature · doi:10.1038/nature06145 · Cited by 1,392

Flagged first, then by citations

Show all 46 references

Sorted by citations

Items 601–700 of 807

Epimutations and Their Effect on Chromatin Organization: Exciting Avenues for Cancer Treatment
Mohammad, A., & Jha, S. (2022) · Cancers · doi:10.3390/cancers15010215 · Cited by 6
Benefits and Challenges of Inhibiting EZH2 in Malignant Pleural Mesothelioma
Khatib, M. O. A., Pinton, G., Moro, L., & Porta, C. (2023) · Cancers · doi:10.3390/cancers15051537 · Cited by 7
Stopping a chromatin enzyme
Simon, J. A. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1088 · Cited by 6
18F-Labeled PET Probe Targeting Enhancer of Zeste Homologue 2 (EZH2) for Cancer Imaging
Yu, L., Despotovic, N., Kovacs, M. S., Pin, C. L., & Luyt, L. G. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00613 · Cited by 6
Inhibition of Ezh2 In Vitro and the Decline of Ezh2 in Developing Midbrain Promote Dopaminergic Neurons Differentiation Through Modifying H3K27me3
Hong, F., Zhao, M., Zhang, L. J., & Feng, L. (2019) · Stem Cells and Development · doi:10.1089/scd.2018.0258 · Cited by 6
Carcinogenic roles and therapeutic effects of EZH2 in gynecological cancers
Wan, Z., Jiang, H., Li, L., Zhu, S., Hou, J., & Yu, Y. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115379 · Cited by 6
EZH2 and MMSET Were Identified as Potentially Useful Therapeutic Targets in Metaplastic Breast Carcinoma
NAKAYAMA, H., Kawachi, K., Suganuma, N., Yoshida, T., Yamashita, T., Yamanaka, T., Matsubara, Y., Kohagura, K., Toda, S., Nakamura, Y., et al. (2020) · Anticancer Research · doi:10.21873/anticanres.14172 · Cited by 6
Posttranslational modifications in Helicobacter pylori-associated gastric pathogenesis: Bridging inflammation and carcinogenesis
Li, W., Liu, T., Wu, T., Cai, T., Wang, F. W., & Zhang, M. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189492 · Cited by 5
Au cœur d’une complexité biologique
Koubi, M., Chabannon, C., & Duprez, E. (2017) · médecine/sciences · doi:10.1051/medsci/20173305013 · Cited by 5
In Vitro Long-Term Proliferation Assays to Study Antiproliferative Effects of PARP Inhibitors on Cancer Cells
Keilhack, H., & Chang, P. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6993-7_21 · Cited by 5
Self-citation
Genetic Impairments of PRC2 Activity in Oncology: Problems and Prospects
Chetverina, D., Ломаев, Д. В., Georgiev, P. G., & Erokhin, M. (2021) · Russian Journal of Genetics · doi:10.1134/s1022795421030042 · Cited by 5
Modulating PCGF4/BMI1 Stability Is an Efficient Metastasis-Regulatory Strategy Used by Distinct Subtypes of Cancer-Associated Fibroblasts in Intrahepatic Cholangiocarcinoma
Hu, J., Xu, H., Ma, X., Bai, M., Zhou, Y., Miao, R., Wang, F., Li, X., & Cheng, B. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.03.012 · Cited by 5
EZH2: a potential new target in T-cell lymphoma?
Giulino-Roth, L. G. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.987770 · Cited by 5
Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer
Walsh, L., Gallagher, W. M., O’Connor, D. P., & Chonghaile, T. N. (2016) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2016.1156534 · Cited by 5
Preparation, Biochemical Analysis, and Structure Determination of SET Domain Histone Methyltransferases
Bergamin, E., & Couture, J. F. (2016) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2016.01.004 · Cited by 5
Nonclinical safety assessment of epigenetic modulatory drugs: Current status and industry perspective
Reynolds, V. L., Butler, P., Abernathy, M. M., Aschenbrenner, L. M., Best, D. D., Blank, J., Crosby, M. E., Custer, L. L., Escobar, P. A., Kolaja, K. L., et al. (2020) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2020.104746 · Cited by 5
Comprehensive Assessment and Classification of High-Grade B-cell Lymphomas
Behdad, A., & Bailey, N. G. (2016) · Surgical pathology clinics · doi:10.1016/j.path.2015.09.008 · Cited by 5
Discovery and Development of Small Molecules Targeting Epigenetic Enzymes with Computational Methods
Meng, F., Wang, C., Wan, W., Lu, W., Lu, W., & Luo, C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802808-7.00004-6 · Cited by 5
Development of Machine Learning Models for Accurately Predicting and Ranking the Activity of Lead Molecules to Inhibit PRC2 Dependent Cancer
Danishuddin, M., Kumar, V., Parate, S., Bahuguna, A., Lee, G., Kim, M. O., & Lee, K. W. (2021) · Pharmaceuticals · doi:10.3390/ph14070699 · Cited by 5
Aberrant histone modifications in pediatric brain tumors
Hamanishi, E. T., Dang, D., & Venneti, S. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1587157 · Cited by 4
An updated patent review of EZH2 inhibitors (2024–present)
Wan, G., Li, S., Tang, Q., Qiu, H., Zhang, Q., & Yu, L. (2025) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2025.2483399 · Cited by 4
AURKA / PLK1 / CDC25C Axis as a Novel Therapeutic Target in INI1 ‐Deficient Epithelioid Sarcoma
Inoue, A., Outani, H., Imura, Y., Nakai, S., Takami, H., Kotani, Y., Mae, H., & Okada, S. (2025) · Cancer Science · doi:10.1111/cas.16438 · Cited by 4
Histone Methyltransferase Activity Assays
Ma, H., Howitz, K. T., Horiuchi, K. Y., & Wang, Y. (2015) · Royal Society of Chemistry eBooks · doi:10.1039/9781782628484-00267 · Cited by 3
Gene Transcription as a Therapeutic Target in Leukemia
Khamidullina, A. I., Varlamova, E. A., Hammoud, N. A., Yastrebova, M. A., & Bruter, A. V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147340 · Cited by 4
Orchestrating epigenetic readers: Progress in understanding the functions of bromodomain-containing protein 4 complexes
Brasier, A. R. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.03.024 · Cited by 4
Childhood medulloblastoma: current and future treatment strategies
Hennika, T., & Gururangan, S. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1087311 · Cited by 4
Epigenetic Modulators
Duncan, K. W., & Campbell, J. E. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2017_30 · Cited by 4
Epigenetic analysis in cancer research
Tyagi, L., Kumar, U., Mishra, S., Simran, S., Rathi, G., & Parashar, D. (2025) · Methods in cell biology · doi:10.1016/bs.mcb.2025.02.021 · Cited by 3
Therapeutic horizons in the development of PROTAC-based EZH2 inhibitors: recent achievements, comparative analysis, and future perspectives
Abulkhair, H. S. (2026) · RSC Advances · doi:10.1039/d5ra08746e · Cited by 3
Epigenetic therapy gains momentum
Seton-Rogers, S. E. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3402 · Cited by 3
Autophagic effect of SAM-competitive EZH2 inhibitors on cancer cells
(2015) · Cancer Cell & Microenvironment · doi:10.14800/ccm.551 · Cited by 3
554 Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells
Brown, R. E., Fuchter, M., Curry, E. W., Green, I. A., Kandil, S., Cherblanc, F., Payne, L., Chapman‐Rothe, N., Shamsaei, E., Srimongkolpithak, N., et al. (2014) · European Journal of Cancer · doi:10.1016/s0959-8049(14)70680-x · Cited by 3
Novel Drugs Targeting the Epigenome
Chen, Z., & Li, H. (2017) · Current Pharmacology Reports · doi:10.1007/s40495-017-0100-7 · Cited by 3
Histone methylation modifiers in medical therapeutics
Trojer, P. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823928-5.00020-7 · Cited by 3
Protein Lysine Methyltransferases Inhibitors
Li, Y., Ding, L., Ren, S., Zhang, W., & Rao, G. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220829151257 · Cited by 3
Epigenetic Factors: Key Regulators Targeted in Cancers
Yeo-Teh, N. S. L., Ito, Y., & Jha, S. (2018) · InTech eBooks · doi:10.5772/intechopen.73040 · Cited by 3
Pathobiology of pancreatic cancer: implications on therapy
Regel, I., Hausmann, S., Benitz, S., Esposito, I., & Kleeff, J. H. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1129276 · Cited by 3
EZH2 Inhibitor GSK126: Metabolism, drug transporter and rat pharmacokinetic studies
Kumar, A., & Wempe, M. F. (2015) · Medical Research Archives · doi:10.18103/mra.v0i3.273 · Cited by 3
Characterization of Inhibitor Binding Through Multiple Inhibitor Analysis: A Novel Local Fitting Method
Riera, T. V., Wigle, T. J., & Copeland, R. A. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3673-1_2 · Cited by 3
Self-citation
Misregulation of Histone Methylation Regulators in Cancer
Ooi, W. F., Yao, X., Tan, P. B. O., & Teh, B. T. (2017) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-59786-7_8 · Cited by 3
Recent Advances in Chemical Tools for the Regulation and Study of Protein Lysine Methyltransferases
Hirano, T., Mori, S., & Kagechika, H. (2018) · The Chemical Record · doi:10.1002/tcr.201800034 · Cited by 3
Pathology and Molecular Pathogenesis of DLBCL and Related Entities
Pasqualucci, L., & Ott, G. (2018) · Methods in molecular biology · doi:10.1007/978-3-030-00362-3_2 · Cited by 4
Chromatin dynamics underlying latent responses to xenobiotics
Moggs, J. G., & Terranova, R. (2018) · Toxicology Research · doi:10.1039/c7tx00317j · Cited by 3
Priming Epigenetic Landscape at Gene Promoters through Transcriptional Activation in Mammalian Germ CellsPreprint
Li, P., Fujisawa, T., Narita, H., Uneme, Y., Seki, M., Hu, M., Narumi, R., Namekawa, S. H., Khan, S. S., Davie, J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.24.625111 · Cited by 3
Derepressing of STAT3 and USP7 contributes to resistance of DLBCL to EZH2 inhibition
He, C., Zhou, W., Jin, X., & Zhou, H. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20650 · Cited by 3
GSK343, an inhibitor of EZH2, prevents acquired cisplatin resistance in bladder cancer
He, L., & Liu, P. (2025) · Molecular Genetics and Genomics · doi:10.1007/s00438-025-02273-3 · Cited by 2
Chromatin Regulatory Targets for Anticancer Therapeutics
Barta, P. A., Carter, T. R., & Erb, M. A. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00231 · Cited by 2
Deep learning and molecular dynamics reveal promising EZH2 inhibitors for epigenetic cancer targeting
Omoboyowa, D. A., Aribigbola, T. C., Aiyeku, B., Bodun, D. S., & Oyeneyin, O. E. (2025) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2025.108784 · Cited by 2
An EZH2–SREBP2 axis promotes cholesterol biosynthesis and represents a noncanonical vulnerability in tumorigenesis
Kim, A., Pan, B., Yu, X., Gao, X., Khudaverdyan, N., Taherian, F., Xu, C., Zhong, H., Xiong, Y., Kanıskan, H. Ü., et al. (2026) · Nature Cell Biology · doi:10.1038/s41556-026-02048-x · Cited by 2
Self-citation
New method for synthesis of EZH2 methyltransferase inhibitor GSK126
Lu, C. H., Zhang, Q., & Chen, X. (2016) · Synthetic Communications · doi:10.1080/00397911.2016.1193875 · Cited by 2
Activating Mutations of the EZH2 Histone Methyltransferase in Cancer
Kruger, R. G., Graves, A. P., & McCabe, M. T. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809737-3.00011-8 · Cited by 2
Small Molecule Inhibitors Targeting New Targets of Protein-Protein Interactions
Yue, L., Wan, W., Xu, P., Li, L., Wang, C., Zhang, Y., Xu, H., Zhang, R., Hu, J., Lu, W., et al. (2018) · Springer eBooks · doi:10.1007/978-981-13-0773-7_7 · Cited by 2
Intriguing Origins of Protein Lysine Methylation: Influencing Cell Function Through Dynamic Methylation
Mezey, N., Cho, W. C. S., & Biggar, K. K. (2019) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2019.03.005 · Cited by 2
Targeting the PRC2-dependent epigenetic program alleviates urinary tract infections
Guo, C., Zhao, M., Sui, X., Balsara, Z. R., Zhai, S., Ahdoot, M. A., Zhang, Y., Lam, C. M., Zhu, P., & Li, X. (2023) · iScience · doi:10.1016/j.isci.2023.106925 · Cited by 2
Polycomb Repressive Complex 2 in Oncology
Guo, Y., Yu, Y., & Wang, G. G. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-45654-1_9 · Cited by 2
Unraveling the Roles of Canonical and Noncanonical PRC1 Complexes
Conway, E., & Bracken, A. P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809737-3.00004-0 · Cited by 2
EZH2 as a therapeutic target in solid tumors
(2015) · Cancer Cell & Microenvironment · doi:10.14800/ccm.1024 · Cited by 2
Epigenetik
Walter, J., & Hümpel, A. (2017) · Nomos Verlagsgesellschaft mbH & Co. KG eBooks · doi:10.5771/9783845270838 · Cited by 1
Neuroblastoma Epigenetic Landscape: Drugging Opportunities
Veschi, V., Durinck, K., Thiele, C. J., & Speleman, F. (2024) · Pediatric oncology · doi:10.1007/978-3-031-51292-6_5 · Cited by 2
Targeting Histone Methylation
Licciardello, M. P., & Kubicek, S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802208-5.00009-6 · Cited by 2
EZH2 Abundance Regulated by UHRF1/UBE2L6/UBR4 Ubiquitin System is the Potential Therapeutic Target to Trigger Pigmented Phenotype in MelanomaPreprint
Abali, G. K., Zhang, Y., Szeto, P., Zhao, P., Moghaddam, S. M., Leece, I., Huang, C., Cheung, J. G., Ameratunga, M., Noguchi, F., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.04.433988 · Cited by 2
Genetic and Epigenetic Profiling in Personalized Medicine: Advances in Treatment of Acute Myeloid Leukemia
Pavlović, S., & Tos̆ić, N. (2019) · Europeanization and globalization · doi:10.1007/978-3-030-16465-2_28 · Cited by 1
Radiosynthesis of [11C]EI1 for imaging EZH2 using positron emission tomography
Wang, H., Lan, Y., Bai, P., Chen, Z., Luo, S., Xu, Y., Fiedler, S. A., Striar, R., & Wang, C. (2020) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02633-1 · Cited by 1
Identification of SET/EED Dual Binders As Innovative PRC2 Inhibitors
Catalano, R., Maruca, A., Rocca, R., Tassone, P., Panzarella, G., Costa, G., Ortuso, F., & Alcaro, S. (2022) · Future Medicinal Chemistry · doi:10.4155/fmc-2022-0010 · Cited by 1
Biological Evaluation of a Novel Compound with Predicted EZH2 and EED Binding Against Human Malignant Melanoma Cells
Gorbunov, S., Kyriakou, S., Anestopoulos, I., Khoso, S., Manfredi, M., Franco, R., Pappa, A., & Panayiotidis, M. I. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062647 · Cited by 1
Targeting EZH2 in Cancer: From Molecular Mechanisms to Clinical Translation
Zhong, X., Li, J., Pan, M., Ke, X., & Cui, H. (2026) · MedComm – Oncology · doi:10.1002/mog2.70070 · Cited by 1
Allosteric Inhibition of Polycomb Repressive Complex 2 by an EZH2‐Selective Small Molecule Inhibitor
Cao, T., Liu, D., Gao, H., Qin, C., Zhang, W., Lu, Z., Tan, D., Qu, Y.-X., Liu, Y., Zou, Z., et al. (2026) · Advanced Science · doi:10.1002/advs.76025 · Cited by 1
From design to clinic: Medicinal chemistry and pharmacology of approved epigenetic drugs
Penteado, A. B., Hassanie, H., Sousa, G. H. M., Vinha, T. C. N., Soares, A. C. G., Calil, R. L., dos Santos, T., Novais, R. M., Emery, F. D. S., Ganesan, A., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119198 · Cited by 1
Emerging Epigenetic Therapies—Lysine Methyltransferase/PRC Complex Inhibitors
Pande, V., Pocalyko, D. J., & Dhanak, D. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800206-3.00019-7 · Cited by 1
Inhibitors of Jumonji C-Domain Histone Demethylases
Staller, P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800206-3.00020-3 · Cited by 1
Polycomb group genes as the key regulators in gene silencing
Su, S., Zhang, M., Li, L., & Wu, M. (2014) · Wuhan University Journal of Natural Sciences · doi:10.1007/s11859-014-0971-y · Cited by 1
504: Functional proteomic analysis of leukaemogenic protein tyrosine kinase targets
Azmi, N., Pierce, A., Williamson, A. J. K., & Whetton, A. D. (2014) · European Journal of Cancer · doi:10.1016/s0959-8049(14)50449-2 · Cited by 1
Trithorax and polycomb cooperation in MLL fusion acute leukemia
Méreau, H., & Schwaller, J. (2013) · Haematologica · doi:10.3324/haematol.2013.084301 · Cited by 1
DNA and Histone Modifications in Cancer Therapy
Suzuki, T. (2017) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-59786-7_20 · Cited by 1
Epigenetic therapies—update on lysine methyltransferase/PRC complex inhibitors
Kim, S., Barkey, N. M., Atasoylu, O., & Dhanak, D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91367-6.00011-8 · Cited by 1
Therapeutic Targeting of the Regulators of Cancer Epigenomes
Al-Janabi, I. I. (2023) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v5i.128 · Cited by 1
Recent Developments in the Structural Mechanism of Protein Methyltransferase Inhibition
Leung, R., & Schapira, M. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674916-00084 · Cited by 1
Epigenetic drugs
Cacabelos, R., Naidoo, V., Tellado, I., Corzo, L., Cacabelos, N., Cacabelos, P., Martínez-Iglesias, O. A., & Segre, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-18722-3.00029-3 · Cited by 1
Therapeutic Applications of the Prostate Cancer Epigenome
Perry, A. S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800206-3.00011-2 · Cited by 1
Histone Methylation Modifiers in Medical Therapeutics
Trojer, P. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803239-8.00037-5 · Cited by 1
Exploring the role of EZH2 (PRC2) as epigenetic target
Aier, I., & Raj, U. (2016) · International Conference on Bioinformatics and Systems Biology (BSB) · doi:10.1109/bsb.2016.7552131 · Cited by 1
Standard Chemotherapy Options and Clinical Trials of Novel Agents for Mesothelioma
Zauderer, M. G. (2017) · Current cancer research · doi:10.1007/978-3-319-53560-9_15 · Cited by 1
DNA and Histone Methylation in Prostate Cancer
Xu, K. (2017) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-59786-7_18 · Cited by 1
Control of Gene Expression by Nuclear Retinoic Acid Receptors
Carrier, M., & Rochette‐Egly, C. (2015) · doi:10.1002/9781118628003.ch5 · Cited by 1
Selective Small‐Molecule Inhibitors of Protein Methyltransferases
Kanıskan, H. Ü., & Jin, J. J. (2019) · Methods and principles in medicinal chemistry · doi:10.1002/9783527809257.ch9 · Cited by 1
Epigenetic Proteins as Emerging Drug Targets
Boriack‐Sjodin, P. A. (2020) · Wiley eBooks · doi:10.1002/9781118681121.ch18 · Cited by 1
A non-canonical EZH2 function sensitizes solid tumors to genotoxic stressPreprint
Liao, Y., Chen, C.-H., Shah, N., Xiao, T., Feit, A. S., Yang, M., Cai, C., Gao, S., Xue, P., Liu, Z., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.11.291534 · Cited by 1
The Function of the ASH1L Histone Methyltransferase in Cancer: A Chemical Biology Approach
Rogawski, D. S. (2016) · Deep Blue (University of Michigan) · Cited by 1
Heterochromatin fidelity is a therapeutic vulnerability in lymphoma and other human cancersPreprint
Najia, M. A. T., Jha, D. K., Zhang, C., Laurent, B., Kubaczka, C., Markel, A., Li, C., Morris, V., Tompkins, A., Hensch, L. T., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.31.635709 · Cited by 1
Animal Model Study of Epigenetic Inhibitors
Chen, A., & Huang, G. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801080-8.00020-x
New class of compounds - variators - are reprogramming substrate specificity of H3K4me3 epigenetic marks reading PHD domain of BPTF proteinPreprint
Yakovenko, O., Leelakumari, S., Vashchenko, G., Cheung, P., Badiong, A., & Jones, S. J. M. (2015) · arXiv (Cornell University) · doi:10.48550/arxiv.1506.06433
Design, synthesis and biological evaluation of small molecules as modulators of histone methyltransferases and demethylases
Tomassi, S. (2014)
Chemical Cryptology of Cancer’s Histone Code
Kulkarni, R. A., & Meier, J. L. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.11.003
Familial and Somatic Mutations of Histone-Modifying Enzymes in Cancer
Liu, C., & Stein, L. D. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7931-4_4
Title Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis( Main article )
Asoke, K., & Casola, S. S. (2013)
Chromatin complex, crystal clear
Schapira, M. (2015) · Science · doi:10.1126/science.aad5203
NEXT STEPS IN FRONT-LINE TREATMENT OF LYMPHOMA: THE ROAD AHEAD Summary of Presentations from the Celgene-Sponsored Satellite Symposium, held at the 19 th EHA Congress,
Cheson, B. D., Zelenetz, A. D., Dreyling, M. H., Coiffier, B., Orsola‐Malpighi, S., & Ludwig Maximilians-University (2014)
Targeting Histone Lysine Methyltransferases in Cancer
Trojer, P. (2015) · Royal Society of Chemistry eBooks · doi:10.1039/9781782628484-00127
[The progress of diagnostic and prognostic molecular markers of lymphoma].
Zhang, M., Shi, Y., & Han, X. (2015) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2015.04.022
The genetics of mature B‐cell malignancies
Strefford, J. C., Fitzgibbon, J., Rose-Zerilli, M. J. J., & Bödör, C. (2016) · Wiley eBooks · doi:10.1002/9781118527948.ch6

Authors: Knutson, S. K., Wigle, T. J., Warholic, N. M., Sneeringer, C. J., Allain, C. J., Klaus, C. R., Sacks, J. D., Raimondi, A., Majer, C. R., Song, J., Scott, M. P., Jin, L., Smith, J. J., Olhava, E. J., Chesworth, R., Moyer, M. P., Richon, V. M., Copeland, R. A., Keilhack, H., Pollock, R. M., & Kuntz, K. W.
Affiliations: Epizyme (United States) (US)
Corresponding author: Kuntz, Kevin W
ORCID: Knutson, Sarah K
Wigle, Tim J
Klaus, Christine R
Raimondi, Alejandra
Song, Jeffrey
Jin, Lei
Smith, Jesse J
Copeland, Robert A
Pollock, Roy M
Venue: Nature Chemical Biology
Publisher: Springer Science and Business Media LLC
Published: 2012-09-30
Volume: 8
Issue: 11
Pages: 890-896
ISSN: 1552-4450 (ISSN-L)
1552-4469
DOI: 10.1038/nchembio.1084
OpenAlex: W2017492512
Cited by: 776
References: 46
Citations by year: 2026: 20 · 2025: 29 · 2024: 29 · 2023: 39 · 2022: 38 · 2021: 49 · 2020: 42 · 2019: 44 · 2018: 60 · 2017: 83 · 2016: 78 · 2015: 97 · 2014: 89 · 2013: 69 · 2012: 10
FWCI: 34.74
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Chemical Biology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer-related gene regulation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: EZH2, H3K27me3, polycomb repressive complex 2, EZH2 inhibitors, non-Hodgkin lymphoma, oncogene addiction, apoptosis, histone methyltransferase inhibitors
MeSH terms: Enhancer of Zeste Homolog 2 Protein, Antineoplastic Agents, Cell Cycle, Dose-Response Relationship, Drug, Enzyme Inhibitors, Histones, Humans, Indazoles, Lymphoma, Lysine, Methylation, Pyridones, Structure-Activity Relationship, Molecular Structure, Cell Death, Point Mutation, Cell Proliferation, Polycomb Repressive Complex 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks